Business Standard

Growth across geographies keeps analysts positive on Aurobindo Pharma

Product launches, acquisitions are expected to drive US, EU prospects

Aurobindo Pharma
Premium

Aurobindo Pharma

Ujjval Jauhari New Delhi
In a quarter which saw its peers struggle, Aurobindo Pharma put out a strong March quarter performance. The company saw a 30.7 per cent growth in revenues, led by a strong 42.7 per cent growth in US sales.

The geography is its single largest, accounting for 47 per cent of overall revenues. This was largely driven by the higher margin injectables business growth, with a ramp-up in antibacterial Ertapenem injection and new launches. The company launched 15 products, including four injectables in the fourth quarter of 2018-19 (FY19). Aurobindo also completed acquisition of seven branded oncology injectable products from Spectrum

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 30 2019 | 8:46 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com